REFERENCES
- Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871–875.
- Tachima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med. 1997;336:138–140.
- Hirsch M, Brun-Vézinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. Recom-mendations of an International AIDS Society-USA Panel. JAMA. 2000.
- Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341(25)1 865–1873.
SUGGESTED READING
- Carr A, Cooper DA. A randomized, multicenter study of pro-tease inhibitor (P1) substitution in aviremic patients with antiretroviral (ARV) lipodystrophy syndrome. In: Programs and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; January 30—February 2, 2000; San Francisco, CA. Abstract 205.
- Carr A, Samaras K, Burton S. A syndrome of peripheral lipodys-trophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51—F58.